首页> 美国卫生研究院文献>Carcinogenesis >Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer
【2h】

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer

机译:在前列腺癌PTEN缺乏的小鼠模型中雄激素剥夺诱导表型可塑性并增强对分子靶向治疗的抵抗力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Castration-resistant prostate cancer is an incurable heterogeneous disease that is characterized by a complex multistep process involving different cellular and biochemical changes brought on by genetic and epigenetic alterations. These changes lead to the activation or overexpression of key survival pathways that also serve as potential therapeutic targets. Despite promising preclinical results, molecular targeted therapies aimed at such signaling pathways have so far been dismal. In the present study, we used a PTEN-deficient mouse model of prostate cancer to show that plasticity in castration-resistant tumors promotes therapeutic escape. Unlike castration-naïve tumors which depend on androgen receptor and PI3K/AKT signal activation for growth and survival, castration-resistant tumors undergo phenotypic plasticity leading to increased intratumoral heterogeneity. These tumors attain highly heterogeneous phenotypes that are characterized by cancer cells relying on alternate signal transduction pathways for growth and survival, such as mitogen-activated protein kinase and janus kinase/signal transducer and activator of transcription, and losing their dependence on PI3K signaling. These features thus enabled castration-resistant tumors to become insensitive to the therapeutic effects of PI3K/AKT targeted therapy. Overall, our findings provide evidence that androgen deprivation drives phenotypic plasticity in prostate cancer cells and implicate it as a crucial contributor to therapeutic resistance in castration-resistant prostate cancer. Therefore, incorporating intratumoral heterogeneity in a dynamic tumor model as a part of preclinical efficacy determination could improve prediction for response and provide better rationale for the development of more effective therapies.
机译:去势抵抗性前列腺癌是一种无法治愈的异质性疾病,其特征是复杂的多步骤过程,涉及由遗传和表观遗传学改变引起的不同细胞和生化变化。这些变化导致关键生存途径的激活或过度表达,这些生存途径也可用作潜在的治疗靶标。尽管临床前的结果令人鼓舞,但迄今为止,针对此类信号通路的分子靶向疗法仍然令人沮丧。在本研究中,我们使用了PTEN缺陷型前列腺癌小鼠模型来显示去势抵抗性肿瘤中的可塑性促进了治疗性逃逸。与依赖雄激素受体和PI3K / AKT信号激活生长和存活的未去势幼稚肿瘤不同,去势抵抗性肿瘤的表型可塑性导致肿瘤内异质性增加。这些肿瘤获得高度异质的表型,其特征是癌细胞依赖于交替的信号转导途径来生长和存活,例如有丝分裂原激活的蛋白激酶和janus激酶/信号转导子以及转录激活子,并失去了对PI3K信号传导的依赖性。这些特征因此使去势抵抗性肿瘤变得对PI3K / AKT靶向疗法的治疗效果不敏感。总体而言,我们的发现提供了证据,表明雄激素剥夺会驱动前列腺癌细胞的表型可塑性,并暗示其是去势抵抗性前列腺癌治疗耐药性的关键因素。因此,将肿瘤内异质性纳入动态肿瘤模型作为临床前疗效确定的一部分可以改善对反应的预测,并为开发更有效的疗法提供更好的理由。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号